Patents Assigned to Gene Shears Pty. Ltd.
  • Patent number: 6207883
    Abstract: This invention relates to a gene associated with male fertility, labeled Ms41-A, and a recessive mutant form thereof, labelled ms41-A, which confers male sterility. The Ms41-A gene is isolated from Arabidopsis, while the related gene Zm41-A is isolated from maize. Male-sterile plants are useful for the production of hybrid plants by sexual hybridization.
    Type: Grant
    Filed: June 22, 1998
    Date of Patent: March 27, 2001
    Assignee: Gene Shears Pty. Ltd.
    Inventors: Gaelle Baudot, Denise Garcia, Rachel Hodge, Pascual Perez
  • Patent number: 6127114
    Abstract: Compounds having highly specific endoribonuclease activity are described. The compounds of this invention, also known as ribozymes, comprise ribonucleotides having two hybridizing regions with predetermined sequences capable of hybridizing with a plant, animal or viral target RNA, a region of defined sequence and a base paired stem region.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: October 3, 2000
    Assignee: Gene Shears Pty. Ltd.
    Inventors: James Phillip Haseloff, Wayne Lyle Gerlach, Philip Anthony Jennings, Fiona Helen Cameron
  • Patent number: 6008343
    Abstract: This invention provides catalytic molecules capable of cleaving target nucleotide sequences. More specifically, the invention provides an endonuclease having nucleotide sequences which are of sufficient length to allow hybridisation to a target nucleotide sequence desired to be cleaved. The endonuclease contains a catalytic region comprising ribonucleotides and/or deoxyribonucleotides, or derivatives thereof which act to cleave a phosphodiester bond of the substrate nucleotide sequence. The catalytic region comprises nucleotides or derivatives thereof which are linked by linking groups which may comprise ribonucleotides, deoxyribonucleotides or combinations thereof.The endonucleases of the invention are useful in the cleavage of target RNAs associated with disease in humans and animals and in the inactivation of RNA transcripts in eukaryotic and prokaryotic cells, as well as the cleavage of RNA transcripts in-vitro.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 28, 1999
    Assignee: Gene Shears Pty. Ltd.
    Inventors: Philip Anthony Jennings, Maxine June Mc Call, Philip Hendry
  • Patent number: 5932435
    Abstract: The present invention relates generally to an in vivo system for gene expression and, more particularly, to the use of the system to screen for molecules which are capable of inhibiting, reducing, altering or otherwise modulating expression of a target nucleotide sequence or the activity of a gene product. The in vivo system of the present invention is particularly but not exclusively useful for screening for antisense, sense or ribozyme constructs or transdominant polypeptides, small peptides or other chemical compounds that are capable of inhibiting, reducing, altering or otherwise modulating expression of target genes or target genetic sequences or the activity of target gene products of commercial importance such as in medical, agricultural and industrial fields.
    Type: Grant
    Filed: October 18, 1996
    Date of Patent: August 3, 1999
    Assignee: Gene Shears Pty. Ltd.
    Inventors: David Atkins, Gregory Martin Arndt, Jonathan Goulder Izant
  • Patent number: 5574143
    Abstract: Compounds having highly specific endoribonuclease activity are described. The compounds of this invention, also known as ribozymes, comprise ribonucleotides having two hybridizing regions with predetermined sequences capable of hybridizing with a target RNA, a region of defined sequence and a base paired stem region.
    Type: Grant
    Filed: February 8, 1994
    Date of Patent: November 12, 1996
    Assignee: Gene Shears Pty. Ltd.
    Inventors: James P. Haseloff, Wayne L. Gerlach, Philip A. Jennings, Fiona H. Cameron